---
Kliniske studier og forskning – Helsepersonell
GENERELLE KLINISKE STUDIER
Walsh, Zach, et al. "Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review." BJPsych Open 8.1 (2022).
2022 systematic review of 83 trials.
Kohtala, Samuel. "Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms." Pharmacological Reports (2021): 1-23.
2021 review of neurobiological mechanisms.
Feifel, David, David Dadiomov, and Kelly C Lee. "Safety of repeated administration of parenteral ketamine for depression." Pharmaceuticals 13.7 (2020): 151.
2020 safety review of 6630 patients.
Riva-Posse, Patricio, et al. "Blood pressure safety of subanesthetic ketamine for depression: a report on 684 infusions." Journal of affective disorders 236 (2018): 291-297.
2018 blood pressure safety review.
Singh, I., Morgan, C., Curran, V., Nutt, D., Schlag, A., & McShane, R. (2017). Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. The Lancet Psychiatry, 4(5), 419-426.
2017 review on ethics and safety.
Kishimoto, T., et al. "Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories." Psychological medicine 46.7 (2016): 1459-1472.
2016 safety and efficacy review.
Wan, Le-Ben, et al. "Ketamine safety and tolerability in clinical trials for treatment-resistant depression." The Journal of clinical psychiatry 76.3 (2014): 0-0.
2014 safety review.
Aan Het Rot, Marije, et al. "Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression." Biological psychiatry 67.2 (2010): 139-145.
2010 safety review.
KETAMIN-ASSISTERT PSYKOTERAPI
Mens mange kliniske studier med ketamin for behandling av psykiske lidelser har fokusert primært på selve medisinen, tyder flere tiår med klinisk erfaring på dette feltet og økende mengde empiriske data på at positiv og mer varig terapeutisk endring kan oppnås ved å kombinere behandlingen med nøye strukturert terapi før, under og etter ketamin-øktene. Denne kombinerte tilnærmingen hjelper til med å forberede klienten på deres opplevelser, øker sannsynligheten for positive erfaringer, og bidrar til å integrere det de har vært med på for å oppnå langvarig endring. På denne måten brukes ketamin som et verktøy for å stimulere nevroplastisitet, legge til rette for kognitiv fleksibilitet, og optimalisere forholdene for gunstige effekter av terapien. I løpet av det siste tiåret har resultater fra kliniske studier på rusmiddelbruk og andre psykiske lidelser støttet tilnærmingen med å kombinere ketamin og psykoterapi for å bidra terapeutisk og maksimere varig meningsfull restitusjon til et godt liv.
Mathai, D. S., Mora, V., & Garcia-Romeu, A. (2022). Toward Synergies of Ketamine and Psychotherapy. Frontiers in Psychology, 1203.
2022 on combining ACT therapy with ketamine.
Drozdz, S. J., Goel, A., McGarr, M. W., Katz, J., Ritvo, P., Mattina, G. F., ... & Ladha, K. S. (2022). Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature. Journal of Pain Research, 15, 1691.
2022 systematic narrative review of ketamine-assisted psychotherapy.
Grabski, M., McAndrew, A., Lawn, W., Marsh, B., Raymen, L., Stevens, T., ... & Morgan, C. J. A. (2022). Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder. The American Journal of Psychiatry, appiajp202121030277-appiajp202121030277.
2022 therapy augments effects of ketamine for alcohol use disorder.
Muscat, S. A., Hartelius, G., Crouch, C. R., & Morin, K. W. (2022). Optimized Clinical Strategies for Treatment-Resistant Depression: Integrating Ketamine Protocols with Trauma-and Attachment-Informed Psychotherapy. Psych, 4(1), 119-141.
2022 optimizing ketamine treatment with trauma-informed psychotherapy.
Wilkinson, Samuel T., et al. "Cognitive behavioral therapy to sustain the antidepressant effects of ketamine in treatment-resistant depression: a randomized clinical trial." Psychotherapy and psychosomatics 90.5 (2021): 318-327.
2021 therapy enhances durability of treatment effect.
Greenway, Kyle T., et al. "Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments." Expert Review of Clinical Pharmacology 13.6 (2020): 655-670.
2020 review of therapeutic mechanisms to augment effect.
Mathew, Sanjay J., and Rebecca B. Price. "Ketamine Plus Motivational Enhancement Therapy: Leveraging a Rapid Effect to Promote Enduring Change." American Journal of Psychiatry 177.2 (2020): 107-109.
2020 editorial on Motivational Enhancement Therapy to augment effect.
Hasler, Gregor. "Toward specific ways to combine ketamine and psychotherapy in treating depression." CNS spectrums 25.3 (2020): 445-447.
2020 review of psychotherapeutic mechanisms to augment effect.
Dakwar, Elias, et al. "A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial." American Journal of Psychiatry 177.2 (2020): 125-133.
2020 ketamine combined with motivational enhancement therapy for alcohol use disorder.
Dore, Jennifer, et al. "Ketamine assisted psychotherapy (KAP): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy." Journal of psychoactive drugs 51.2 (2019): 189-198.
2019 data from KAP clinics.
Dakwar, Elias, et al. "A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial." American Journal of Psychiatry 176.11 (2019): 923-930.
2019 mindfulness-based therapy enhances positive effects with cocaine dependence.
KETAMIN MOT DEPRESJON
Jelen, Luke A., and James M. Stone. "Ketamine for depression." International Review of Psychiatry 33.3 (2021): 207-228.
2021 narrative review of ketamine for depression.
McIntyre, Roger S., et al. "Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation." American Journal of Psychiatry 178.5 (2021): 383-399.
2021 international expert opinion.
Walsh, Zach, et al. "Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review." BJPsych Open 8.1 (2022).
2021 systematic review of 83 trials.
Swainson, Jennifer, et al. "The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the use of racemic ketamine in adults with major depressive disorder: Recommandations du groupe de travail du réseau canadien pour les traitements de l’humeur et de l’anxiété (canmat) concernant l’utilisation de la kétamine racémique chez les adultes souffrant de trouble dépressif majeur." The Canadian Journal of Psychiatry 66.2 (2021): 113-125.
2021 Canadian task force recommendations.
Bahji, Anees, Gustavo H. Vazquez, and Carlos A. Zarate Jr. "Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis." Journal of affective disorders 278 (2021): 542-555.
2021 systematic review and meta-analysis.
Kvam, T. M., Stewart, L. H., Blomkvist, A. W., & Andreassen, O. A. (2021). Ketamine for depression–evidence and proposals for practice. Tidsskrift for Den norske legeforening.
2021 brief summary review in the Journal of the Norwegian Medical Association.
Krystal, John H., et al. "Ketamine: a paradigm shift for depression research and treatment." Neuron 101.5 (2019): 774-778.
2019 review.
Wilkinson, Samuel T., et al. "Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression." Psychotherapy and psychosomatics 86.3 (2017): 162-167.
2017 CBT plus ketamine for depression.
Sanacora, Gerard, et al. "A consensus statement on the use of ketamine in the treatment of mood disorders." JAMA psychiatry 74.4 (2017): 399-405.
2017 consensus from the American Psychiatric Association.
Murrough, James W., et al. "Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression." Biological psychiatry 74.4 (2013): 250-256.
2013 trial demonstrating increased durability by repeat treatments.
KETAMIN MOT SELVMORDSTANKER
Hochschild, Annabella, Michael F. Grunebaum, and J. John Mann. "The rapid anti-suicidal ideation effect of ketamine: a systematic review." Preventive medicine 152 (2021): 106524.
2021 systematic review.
Witt, Katrina, et al. "Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials." Australian & New Zealand Journal of Psychiatry 54.1 (2020): 29-45.
2020 systematic review and meta-analysis.
Wilkinson, Samuel T., et al. "The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis." American journal of psychiatry 175.2 (2018): 150-158.
2018 systematic review and meta-analysis.
Grunebaum, Michael F., et al. "Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial." American Journal of Psychiatry 175.4 (2018): 327-335.
2018 large RCT.
KETAMIN MOT RUSLIDELSER
Grabski, M., et al. "Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder." The American Journal of Psychiatry (2022)
2022 KARE study for alcohol use disorder.
Walsh, Zach, et al. "Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review." BJPsych Open 8.1 (2022).
2022 systematic review of 83 trials.
Worrell, Stephen D., and Thomas J. Gould. "Therapeutic Potential of Ketamine for Alcohol Use Disorder." Neuroscience & Biobehavioral Reviews (2021).
2021 review for alcohol use disorder.
Martinotti, Giovanni, et al. "Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature." Brain Sciences 11.7 (2021): 856.
2021 review for addiction, OCD and eating disorders.
Azhari, Nour, et al. "Ketamine-facilitated behavioral treatment for cannabis use disorder: a proof of concept study." The American journal of drug and alcohol abuse 47.1 (2021): 92-97.
2021 ketamine for cannabis use disorder.
Strong, Caroline E., and Mohamed Kabbaj. "Neural Mechanisms Underlying the Rewarding and Therapeutic Effects of Ketamine as a Treatment for Alcohol Use Disorder." Frontiers in Behavioral Neuroscience 14 (2020): 225.
2020 mechanisms for ketamine for alcohol use disorder.
Dakwar, Elias, et al. "A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial." American Journal of Psychiatry 177.2 (2020): 125-133.
2020 ketamine plus motivational therapy for alcohol use disorder.
Dakwar, Elias, et al. "A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial." American Journal of Psychiatry 176.11 (2019): 923-930.
2019 RCT for cocaine dependence.
Dakwar, E., et al. "Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial." Molecular psychiatry 22.1 (2017): 76-81.
2019 RCT for cocaine use disorder.
Das, Ravi K., et al. "Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories." Nature communications 10.1 (2019): 1-10.
2019 ketamine for alcohol use disorder.
Ezquerra-Romano, I. Ivan, et al. "Ketamine for the treatment of addiction: Evidence and potential mechanisms." Neuropharmacology 142 (2018): 72-82.
2018 review of ketamine for substance use disorders.
Jones, Jennifer L., et al. "Efficacy of ketamine in the treatment of substance use disorders: a systematic review." Frontiers in psychiatry 9 (2018): 277.
2018 systematic review of ketamine for substance use disorders.
Morgan, Celia, et al. "Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use." Current Opinion in Behavioral Sciences 13 (2017): 71-76.
2017 review for substance use disorders.
Krupitsky, Evgeny M., et al. "Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence." Journal of psychoactive drugs 39.1 (2007): 13-19.
2007 ketamine for heroin dependence.
Krupitsky, Evgeny, et al. "Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up." Journal of substance abuse treatment 23.4 (2002): 273-283.
2002 ketamine for heroin addiction.
KETAMIN MOT PTSD, ANGSTLIDELSER OG OCD
Feder, Adriana, et al. "A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder." American Journal of Psychiatry 178.2 (2021): 193-202.
2021 RCT for PTSD.
Asim, Muhammad, et al. "Ketamine For Post-Traumatic Stress Disorders And It’s Possible Therapeutic Mechanism." Neurochemistry International (2021): 105044.
2021 review of ketamine for PTSD and putative mechanisms.
Martinotti, Giovanni, et al. "Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature." Brain Sciences 11.7 (2021): 856.
2021 review for addiction, OCD and eating disorders.
Banov, Michael D., et al. "Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature." CNS spectrums 25.3 (2020): 331-342.
2020 review for the treatment of anxiety disorders.
Feder, Adriana, et al. "The emergence of ketamine as a novel treatment for posttraumatic stress disorder." Advances in Pharmacology 89 (2020): 261-286.
2020 review of ketamine for PTSD
Sharma, Lavanya P., et al. "Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder." Asian journal of psychiatry 52 (2020): 102183.
2020 review for the treatment of OCD.
Ross, Cassie, et al. "High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans." Annals of clinical psychiatry: official journal of the American Academy of Clinical Psychiatrists 31.4 (2019): 271-279.
2019 ketamine for PTSD in combat veterans.
Taylor, Jerome H., et al. "Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial." Neuropsychopharmacology 43.2 (2018): 325-333.
2018 RCT for social anxiety disorder.
Veen, Cato, et al. "Subanesthetic dose ketamine in posttraumatic stress disorder: a role for reconsolidation during trauma-focused psychotherapy?." Behavioral neurobiology of PTSD. Springer, Cham, 2018. 137-162.
2018 ketamine with psychotherapy in trauma.
Glue, Paul, et al. "Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders." Journal of Psychopharmacology 31.10 (2017): 1302-1305.
2017 ketamine for treatment resistant anxiety disorders.
Feder, Adriana, et al. "Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial." JAMA psychiatry 71.6 (2014): 681-688.
2014 first RCT of ketamine for chronic PTSD.
Rodriguez, Carolyn I., et al. "Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept." Neuropsychopharmacology 38.12 (2013): 2475-2483.
2013 first RCT with ketamine for OCD.
KETAMIN MOT SPISEFORSTYRRELSER
Keeler, Johanna Louise, et al. "Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review." Nutrients 13.11 (2021): 4158.
2021 review of ketamine for anorexia.
Ragnhildstveit, Anya, et al. "Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions." Brain Sciences 12.3 (2022): 382.
2022 review of ketamine for eating disorders.
Meld deg på vårt nyhetsbrev!
Awakn Clinics Oslo
Øvre Slottsgate 7, 0157 Oslo
oslo@awaknclinics.com
Telefon: +47 21 40 38 19
Awakn Clinics London
18 Dukes Road, WC1H 9PY, London, United Kingdom
london@awaknclinics.com
Telefon: +44 207 387 2596
Awakn Clinics Bristol
1 Regent St, Clifton, Bristol BS8 4HW, United Kingdom
bristol@awaknclinics.com
Telefon: +44 117 985 0439
© 2022 Awakn Life Sciences Corp | Cookie Policy | Terms and Conditions | Privacy Policy
